Erasca, Inc.(ERAS)

Biotechnology · San Diego, CA

$14.72-0.02 (-0.14%)

Delayed quote: Oct 5, 2026, 4:00 PM EDT

EV/FCF Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/FCF ratio is N/A as of 2026-10-06T11:36:27.566Z.

Stored calculation inputs

Calculation as of: 2026-10-06T11:36:27.566Z.

Quote observation: 2026-10-05T20:00:01.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 5,109,709,440
Total debt · period ending 2026-06-30: 44,714,000
Cash · period ending 2026-06-30: 42,542,000
TTM free cash flow · period ending 2026-06-30: -98,081,000

FMP input reference: f97479f440d7a03605f533a56e26179237db48e588053495707f458dff3bcd44

Free Cash Flow|FCF Yield|P/FCF Ratio|EV/EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

ERAS EV/FCF Ratio Metrics

EV/FCF RATIO

N/A

ERAS Competitors' EV/FCF Ratio

ERAS

Erasca, Inc.

Current

Market Cap

$5.11B

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

SRRK

Scholar Rock Holding Corporation

vs ERAS

Market Cap

$5.20B

EV/FCF Ratio

N/A

TTM Avg

29.52x

3Y Avg

29.52x

5Y Avg

29.52x

BLLN

BillionToOne, Inc.

vs ERAS

Market Cap

$5.02B

EV/FCF Ratio

139.01x

TTM Avg

178.16x

3Y Avg

178.16x

5Y Avg

178.16x

MMSI

Merit Medical Systems, Inc.

vs ERAS

Market Cap

$5.20B

EV/FCF Ratio

27.39x

TTM Avg

27.85x

3Y Avg

42.08x

5Y Avg

46.24x

COGT

Cogent Biosciences, Inc.

vs ERAS

Market Cap

$5.27B

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

DNTH

Dianthus Therapeutics, Inc.

vs ERAS

Market Cap

$4.92B

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

DOCS

Doximity, Inc.

vs ERAS

Market Cap

$5.35B

EV/FCF Ratio

16.98x

TTM Avg

20.97x

3Y Avg

34.66x

5Y Avg

46.39x

DFTX

Definium Therapeutics, Inc.

vs ERAS

Market Cap

$4.81B

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ADPT

Adaptive Biotechnologies Corporation

vs ERAS

Market Cap

$4.78B

EV/FCF Ratio

N/A

TTM Avg

17.76x

3Y Avg

17.76x

5Y Avg

17.76x

CRSP

CRISPR Therapeutics AG

vs ERAS

Market Cap

$5.53B

EV/FCF Ratio

N/A

TTM Avg

11.36x

3Y Avg

56.18x

5Y Avg

56.18x

NAME	MARKET CAP	EV/FCF RATIO	TTM	3Y	5Y
Erasca, Inc. (ERAS)	$5.11B	N/A	N/A	N/A	N/A
Scholar Rock Holding Corporation (SRRK)vs ›	$5.20B	N/A	29.52x	29.52x	29.52x
BillionToOne, Inc. (BLLN)vs ›	$5.02B	139.01x	178.16x	178.16x	178.16x
Merit Medical Systems, Inc. (MMSI)vs ›	$5.20B	27.39x	27.85x	42.08x	46.24x
Cogent Biosciences, Inc. (COGT)vs ›	$5.27B	N/A	N/A	N/A	N/A
Dianthus Therapeutics, Inc. (DNTH)vs ›	$4.92B	N/A	N/A	N/A	N/A
Doximity, Inc. (DOCS)vs ›	$5.35B	16.98x	20.97x	34.66x	46.39x
Definium Therapeutics, Inc. (DFTX)vs ›	$4.81B	N/A	N/A	N/A	N/A
Adaptive Biotechnologies Corporation (ADPT)vs ›	$4.78B	N/A	17.76x	17.76x	17.76x
CRISPR Therapeutics AG (CRSP)vs ›	$5.53B	N/A	11.36x	56.18x	56.18x

Cash Flow Valuation Comparison

EV/FCF

N/A

P/FCF

N/A

FCF Yield

N/A

Formula: EV/FCF = Enterprise Value / Free Cash Flow

EV/FCF vs P/FCF:

EV/FCF accounts for debt and cash through enterprise value
P/FCF only considers equity value
EV/FCF can be compared across companies with different debt levels
Both measure how the market values cash generation

EV/FCF Ratio Formula & Definition

EV/FCF = Enterprise Value / Free Cash Flow (TTM)

Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

About Erasca, Inc.

Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to address non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor targeting patients with advanced or metastatic solid tumors. Additionally, Erasca is progressing ERAS-801, an EGFR inhibitor capable of penetrating the central nervous system, intended for recurrent glioblastoma multiforme. The company was founded in 2018 and maintains its headquarters in San Diego, California.

San Diego, CA

103 employees

www.erasca.com

Healthcare / Biotechnology